RVPHW
Reviva Pharmaceuticals Holdings, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.041
- Prev close
- 0.0036
- Mkt cap
- 343.91K
- Vol
- 303.38K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.003
- High
- 0.0046
- Forward P/E
- 0.00
- Beta
- -0.06
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.68
- EPS (TTM)
- 0.00
- Beta
- -0.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -17.42M
- Total cash
- 6.18M
- Total debt
- 207.50K
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- revivapharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on RVPHW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Walleye Capital LLC | 0.53% | 33,718 | 4.69K | Sep 29, 2024 |
| Walleye Trading LLC | 0.41% | 25,727 | 3.58K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 666 | 92 | Sep 29, 2024 |